AbbVie (ABBV) Tops Q2 EPS by 6c; Boosts FY16 EPS Outlook

July 29, 2016 7:38 AM EDT

Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.

AbbVie (NYSE: ABBV) reported Q2 EPS of $1.26, $0.06 better than the analyst estimate of $1.20. Revenue for the quarter came in at $6.43 billion versus the consensus estimate of $6.2 billion.


  • Global HUMIRA sales increased 17.4 percent on a reported basis. Operational HUMIRA sales increased 17.7 percent, excluding a modest impact of foreign exchange. Strong global growth was driven by continued momentum across all three major market categories – rheumatology, dermatology and gastroenterology.
  • Second-quarter global IMBRUVICA net revenue was $439 million, with U.S. sales of $384 million and international profit sharing of $55 million for the quarter.
  • Total company revenue growth was also driven by $419 million in global VIEKIRA sales in the quarter, as well as strong operational growth from Duodopa, Creon and Lupron.


AbbVie sees FY2016 EPS of $4.73 - $4.83, versus prior guidance of $4.62 - $4.82 and the consensus of $4.75. he company's 2016 adjusted diluted EPS guidance excludes $0.91 per share of intangible asset amortization expense, acquisition related costs and accounting impacts, the impact of the Venezuelan currency devaluation, and other specified items.

For earnings history and earnings-related data on AbbVie (ABBV) click here.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Earnings, Guidance, Hot Earnings, Hot Guidance, Trader Talk

Related Entities

Earnings, Definitive Agreement